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Abstract  
BACKGROUND: Acute lymphocytic leukemia (ALL) is the most common hematologic malignancy 
in children. In young children it is also largely curable, with more than 90% of afflicted children 
achieving long-term remission. PRAME (Preferentially expressed antigen of melanoma) gene 
belongs to Group 3 class I HLA-restricted widely expressed antigens in which genes encoding widely 
expressed tumor antigens have been detected in many normal tissues as well as in histologically 
different types of tumors with no preferential expression on a certain type of cancer. It has been 
found to be expressed in a variety of cancer cells as leukemia & lymphoma. PRAME monitoring can 
be useful for detection of minimal residual disease and subsequent relapses particularly those 
leukemias in which specific tumor markers are unavailable. Wilms’ tumor1 (WT1) gene was 
identified as a gene that plays an important role in normal kidney development and inactivation of 
its function was shown to result in the development of Wilms’ tumors in paediatric patients. 
Disruption of WT1 function has been implicated in the formation of many different tumor types.  
AIM: to study how PRAME & WT 1 genes expression patterns influence cancer susceptibility & 
prognosis. 
PATIENTS & METHODS: 50 patients with denovo childhood acute lymphoblastic leukemia, as well 
as 50 age and sex matched apparently healthy volunteers were genotyped for PRAME and WT1 
genes expression by reverse transcription polymerase chain reaction (RT-PCR). 
RESULTS: PRAME gene was expressed in 34 of the patients (68%) and WT1 gene was expressed 
in 26 of the patients (52%). Expression of both genes was significantly higher compared to controls 
(P < 0.0001). Analysis of relapse free survival among our patients revealed that patients expressing 
PRAME gene or WT1 gene had better relapse free survival (p value=0.02 and 0.01 respectively). 
Relapse free survival increased significantly among patients coexpressing PRAME and WT 1(p 
value =0.001). 
CONCLUSION: It is concluded that the expression of PRAME and WT1 genes are indicators of 
favorable prognosis and can be useful tools for monitoring minimal residual disease (MRD) in acute 
leukemia especially in patients without known genetic markers. Differential expression between 
acute leukemia patients and healthy volunteers suggests that the immunogenic antigens (PRAME 
and WT1) are potential candidates for immunotherapy in childhood acute leukemia. 
 
 
 
Introduction 
 
 Acute lymphoblastic leukemia (ALL) is the 
most common malignant disease in children younger 
than 15 years in Western countries [1]. 
The incidence of ALL decreases with age, 
and although it is the most common childhood cancer, 
the disease remains less prevalent in adolescents and 
adults. In pediatric studies, children over the age of 10 
years display worse outcomes, but in adult registries 
younger patients appear to do better than older 
patients [2-4]. 
PRAME (Preferentially expressed antigen of 
melanoma) was first isolated as a human melanoma 
antigen recognized by Cytotoxic T cells (CTL). It 
encodes for a protein consisting of 509 amino acids 
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and its function was unknown [5]. It has been found to 
be expressed in a variety of cancer cells as leukemia, 
lymphoma [6] and non-small-cell lung carcinoma [7], 
renal cell carcinoma [8], mammary carcinoma, 
sarcomas and head & neck tumors using semi 
quantitative RT-PCR [9].PRAME monitoring can be 
useful for detection of minimal residual disease and 
subsequent relapses particularly those leukemias in 
which specific tumor markers are unavailable [10]. 
WT1 was identified as a gene that plays an 
important role in normal kidney development and 
inactivation of its function was shown to result in the 
development of Wilms’ tumors in paediatric patients. 
Using quantitative real time PCR and 
immunohistochemistry [11], presented data showed 
that WT1 is not only highly expressed in leukaemia 
but also in a variety of nonhaematopoetic 
malignancies including lung cancer, colon cancer and 
pancreatic carcinomas. 
Constitutive expression of wild-type or mutant 
WT1 has been demonstrated in variety of hematologic 
malignancies and, particularly, in blasts of nearly all 
acute leukemias irrespective of lineage-specificity. 
Therefore, WT1 expression may be regarded as a 
nonspecific "panleukemic" molecular marker [12]. 
In normal peripheral blood (PB) and bone 
marrow (BM), WT1 expression is reported to be low 
and sometimes undetectable even by qualitative 
reverse transcriptase polymerase chain reaction (RT-
PCR). By contrast, WT1 is highly expressed in most 
acute leukemias and its level of expression is 
associated with the presence, persistence, or 
reappearance of leukemic hematopoiesis [13]. 
Because the WT1 gene is expressed at low 
levels even in normal hematopoietic stem cells, most 
studies using qualitative or semi-quantitative analyses 
of WT1 transcripts have produced positive results with 
regard to the prediction of relapse. Early recognition of 
relapse at the molecular level provides a window for 
therapeutic intervention while the burden of disease is 
still relatively low [14]. 
The aim of this work was to study how 
PRAME & WT 1 genes expression patterns influence 
cancer susceptibility & prognosis and to be correlated 
with survival. 
 
 
Patients and Methods 
 
The current study was carried out on 50 
patients with denovo childhood acute lymphoblastic 
leukemia (ALL), in the period between June 2009 and 
March 2010, among cases referred to nuclear 
medicine and oncology unit, pediatric hospital of Kasr 
El Eini school of medicine, Cairo University, with 
follow up period of 18 months, as well as 50 age and 
sex matched apparently healthy volunteers. Cases 
were diagnosed according to WHO criteria. The 
diagnosis of ALL was based on morphological and 
phenotypic data.  
Patients were 30 males and 20 females. Age 
ranged from 2 to 15 years. Fifty age and sex matched 
apparently healthy volunteers were enrolled as control 
group. These individuals were volunteers who had no 
medical history of any type of cancer or other 
diseases and were not related to the patients. They 
were 33 males and 17 females. Their ages ranged 
between 7and 16 years. All patients and controls were 
analyzed for clinical and laboratory findings, including 
full history taking, clinical examination, routine 
laboratory investigations, LDH abdominal ultrasound 
for detection of organomegaly and lymphadenopathy. 
The patients were subjected as well to cytochemical 
and immunophenotypic analysis to confirm diagnosis 
and to divide the patients into their subtypes. Written 
informed consent was obtained from all the 
participants before including them in the study.  
Genotyping for PRAME and WT 1 genes 
expression was performed for both patients and 
controls. Three ml of blood were withdrawn from all 
the subjects included in the study in a sterile 
ethelenediaminetetraacetic acid (EDTA) vacutainer. 
Extraction of total RNA was done using High pure 
RNA isolation kit (Fermentas Germany catalogue 
number; 1828665). Patient RNA was reverse 
transcriped with reverse transcriptase enzyme by 
incubation for 30 minutes at 50°C. Following a 
denaturation step, the cDNA synthesis was carried out 
using random hexamer primers in a total volume of 25 
µl. Subsequently, the cDNA was heated to inactivate 
the reverse transcriptase enzyme and was stored at -
20°C until used for PCR amplification. PRAME and 
WT1 genes expression were determined by using 
superscript one-step RT-PCR system following the 
protocol from Fiedler et al., 1997 [15]. The following 
primer sequences were used: For PRAME gene: 
sense 5'-CCA TGA CAA AGA AGC GAA AA-3' and 
antisense 5'-CAT CTG GCC CAG GTA AGG AG-3', 
for WT-1 gene: sense: 5' -AGAA-TACACACGCACG-
GTGTCT-3', antisense: 5'- GATGCC-
GACCGTACAAGAGTC-3' and for β actin (as an 
internal control): sense: 
5'GGCATCGTCACCAACTGGGACGAC-3', antisense: 
5'-ATTTGCGGTGGACGATGGAGGGGC-3'. 
Amplification of cDNA for PRAME gene was 
done for 35 cycles of: denaturation at 94°C for 1:30 
minutes., annealing at 60°C for 3 minutes, extension 
at 68°C for 4 minutes and final extension at 68°C for 7 
minutes. Amplification of cDNA for WT 1 and β actin 
genes: initial cycle: a precycle of 5 minutes at 94°C, 
45 seconds at 60°C and 45 seconds at 68°C, PCR 
cycles: were 35 cycles of: Denaturation at 94°C for 1 
minute, annealing at 60°C for 1 minute, extension at 
68°C for 2 minutes, final extension 68°C for 7 minutes. 
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The most convenient method of visualizing 
DNA in agarose gel is by staining with the fluorescent 
dye ethidium bromide. The sample was considered 
positive when a clear, sharp, distinct band was 
observed at the specific molecular weight specific for 
PRAME (517bp), WT1 (480bp), β actin (541bp). The 
size of the amplified product was read with the use of 
a DNA marker of different molecular weights (Ladder). 
 
Statistics 
Data were summarized and presented in the 
form of mean, range, percentage and standard 
deviation as descriptive statistics. Descriptive 
statistics and statistical comparison were performed 
using the statistical software program SPSS (version 
16). Comparison was done regarding clinical data 
using the Chi-Square test (2), while for the laboratory 
data. 
Independent T-test and ANOVA test were 
used. Odds ratio to access the risk related to the 
different gene expression. A p-value <0.05 was 
considered to be statistically significant. 
 
 
Results 
 
The current study was carried out on 50 
patients with childhood ALL as well as 50 age and sex 
matched apparently healthy volunteers (as a control 
group). 
Patients included in our study were 30 males 
(60%) and 20 females (40%). Their age ranged 
between 2 to 15 years with a mean value of 10.2 ± 
3.5. Control group were 33 males (66%) and 17 
females (34%). Age ranged between 7 and 16 years 
with a mean of 11.2 ± 4.8. There were no statistically 
significant differences between the 2 groups as regard 
age (p value = 0.2368) or sex (p value = 0.6787). 
Clinical characteristics and laboratory data of patients 
were summarized in Table 1 and Table 2 respectively. 
Table 1: Clinical characteristics of patients. 
  Clinical characteristics Number of patients (50) Percentage (%) 
  Symptoms 
-Fever 
-Bleeding 
-Neurological 
-Bony pains 
-Easy fatiguability 
  Signs 
-No organomegaly 
-Hepatomegaly 
-Splenomegaly 
-Lymphadenopathy 
 
 
13/50 
4/50 
2/50 
15/50 
16/50 
 
3/50 
4/50 
3/50 
40/50 
 
 
26% 
8% 
4% 
30% 
32% 
 
6% 
8% 
6% 
80% 
 
There were highly statistically significant 
differences between the 2 groups regarding the total 
leucocytic count,hemoglobin level and platelet count 
(p value < 0.0001). 
Table 2: Laboratory data of patients and controls. 
  Laboratory data Patients (50) Controls (50) P value 
 
  Total leucocytic count/ mm³ 
   Range   
   Mean±SD: 
   
Hemoglobin (gm %) 
    Range: 
    Mean±SD: 
 
  Platelets ×10³mm³ 
    Range: 
    Mean±SD: 
 
 
2-48.5 
16.7±11.9 
 
 
3.5-11 
7.36±2.14 
 
 
4-123 
56.3±32.9 
 
4.5-10.5 
7.8±1.8 
 
 
11.4-14.6 
13.04±1.05 
 
 
155-200 
173.8±13.6 
 
*   P < 0.0001[HS] 
 
 
 
*   P < 0.0001[HS] 
 
 
 
*   P < 0.0001[HS] 
*[HS]   highly significant:  (P value < 0.001). 
 
Some additional laboratory tests and 
procedures were performed for the patients to 
diagnose ALL and to assess staging and prognostic 
state. 
In the patient group, the serum LDH level 
ranged between 190-366 mg/dl with a mean of 215.6 
± 65.5, peripheral blood blast percentage ranged 
between 10-80 % with a mean of 37.3 ± 23.4, bone 
marrow aspirate blast percentage ranged between 60-
98% with a mean of 80.6 ± 9.97, X rays and CT were 
free in 38 (76%) patients and were involved in 12 
(24%) patients. CSF analysis was free in 48 (96%) 
patients and was involved in 2 (4%) patients.  
As regard the FAB subgroups, 6 (12%) 
patientswere diagnosed as L1, 40 (80%) patients 
were diagnosed as L2, 4 (8%) patients were 
diagnosed as having L3. As regard the flow cytometry 
results, 28 (56%) patients were diagnosed as having 
C-ALL, while 22 (44%) patients were diagnosed as 
having non C-ALL. 
Concerning the results of PRAME gene 
expression (summarized in Table 3): PRAME gene 
was expressed in 34 (68%) of the patients while it was 
only expressed in 2 (4%) of the controls.  
Table 3:  Results of PRAME and WT 1 gene expression  in 
patients and control groups. 
 
Patients 
(n=50) 
Controls 
(n=50) 
P value 
 
-PRAME 
-WT-1 
 
32/50 (64%) 
28/50 (56%) 
 
2/50 (4%) 
1/50 (2%) 
 
P < 0.0001[HS]* 
P < 0.0001[HS]* 
*[HS]   highly significant:  (P value < 0.001). 
 
Concerning the results of WT1 gene 
expression (summarized in Table 3): WT1 gene was 
expressed in 26 (52%) of the patients while it was only 
expressed in 1 (2%) of the controls.  
It was found that there were highly statistically 
significant differences between patient and control 
groups regarding PRAME and WT 1 genes 
expression (P < 0.0001). 
PRAME and WT 1 gene expression and 
response to induction therapy: After chemotherapy, 29 
(58%) patients achieved complete remission, 5 (10%) 
patients achieved only partial remission, 12 (24%) 
patients died, 4 (8%) patients failed to respond to 
induction chemotherapy.  
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Table 4: Summarizes PRAME and WT 1 gene expression and 
survival. 
 
Relapse-free survival 
Number    of 
patients 
in CR 
Median RFS 
(months) 
18 months  RFS 
OR (95% CI) 
P value 
    Total 25 17.3 
0.33 
(0.2-0.55) 
 
 
PRAME 
expressed 
not expressed 
 
 
8 
17 
 
 
17.2 
15.8 
 
 
0.35 (0.34-0.55) 
0.37 (0.35-0.56) 
 
 
0.02[S]* 
 
WT 1 
expressed 
not expressed 
 
 
10 
15 
 
 
17.5 
16.1 
 
 
0.55 (0.4-0.7) 
0.53 (0.4-0.6) 
 
 
0.01[S]* 
PRAME and WT 
coexpression 
expressed 
not expressed 
 
 
 
9 
16 
 
 
17.8 
11.1 
 
0.45 (0.3-0.6) 
0.53 (0.4-0.6) 
 
0.001[HS]** 
Abbreviations: CI: conﬁdence interval  ; RFS: relapse-free survival. *Significant [S]: p 
value<0.05; **[HS]   highly significant:  (P value < 0.001). 
 
PRAME and WT 1 gene expression and 
survival: Among 50 patients, 25 (50%) achieved CR, 
whereas 9 (18%)
 
were resistant during the follow up 
period of 18 months. Death was the adverse outcome 
in 16 (32%) patients. The duration of relapse free 
survival ranged between 0 & 18 months with a mean 
value of 10.8 ± 5.3. At a median follow-up of 18 
months, the univariate analysis revealed that the 
PRAME and WT 1 genes expression were 
significantly associated with better relapse free 
survival (RFS) (p value - 0.02 and 0.01, respectively). 
Relapse free survival increased significantly among 
patients coexpressing PRAME and WT 1 (p value -
0.001)] (summarized in Table 4).  
 
 
Discussion 
 
PRAME is a germinal tissue-specific gene 
that is also expressed at high levels in haematological 
malignancies and solid tumours. The physiological 
functions of PRAME in normal and tumour cells are 
unknown, although a role in the regulation of retinoic 
acid signalling has been proposed [16]. 
Our study revealed that 68% of our denovo 
childhood ALL patients expressed PRAME gene 
which was higher result in comparison to study by 
Steinbach et al., 2002 [17] who studied PRAME gene 
expression in 50 children with newly diagnosed ALL 
using quantitative reverse transcriptase polymerase 
chain reaction. Over expression of PRAME was found 
in 42% of the patients. In agreement to previous 
results, Greiner et al., 2006 [18] reported that PRAME 
gene was expressed in 42% of ALL patients. In 
another study, PRAME expression has been found in 
15–64% of the cases with ALL, and it has been shown 
to correlate with t(9:22) [19]. However, PRAME was 
found in only 5 out of 29 (17.2%) ALL cases by 
Paydas et al., 2005 [20]. 
While PRAME is absent or expressed at very 
low levels in most normal tissues tested, high levels of 
PRAME mRNAs are encountered in malignant cells, 
including the vast majority of primary and metastatic 
melanomas (88% and 95%, respectively) [21]. 
Microarray and PCR studies have shown that PRAME 
is absent in normal haematopoietic tissues including 
bone marrow, CD34+ sorted bone marrow cells, 
unsorted peripheral blood cells and sorted B and T 
lymphocytes [22]. However, numerous studies have 
reported highly elevated levels of PRAME in both 
acute and chronic leukaemias and non-Hodgkin's 
lymphomas [22-24]. 
Relapse free survival was analysed during 
follow up period for 18 months. We found that patients 
expressing PRAME gene had longer relapse free 
survival. Although the role of PRAME in acute 
leukaemia and other cancers is complex, it has 
promise both as a cancer biomarker and as a 
therapeutic target. In AML, PRAME is usually 
associated with a favourable response to 
chemotherapy and prolonged survival [17, 25]. This 
was initially thought to be due to its expression in 
leukaemias having favourable prognoses, such as 
AML M2 with t(8;21), AML M3 with t(15;17) and 
childhood B-ALL [26, 27]. However, PRAME has been 
reported to be an independent prognostic factor in 
AML M3 with t(15;17) [26] and to be associated with 
longer overall survival, even in karyotypes with 
generally poor prognosis such as deletion of the long 
arm of chromosome 7 and monosomy 7 [25]. In 
contrast, over-expression of PRAME mRNA is 
associated with poor prognosis in solid organ 
malignancies [28-30]. This raises the possibility that 
PRAME may have different roles in oncogenesis or 
tumour suppression dependent on the tumour type. 
Therefore, its usefulness in predicting clinical outcome 
in solid tumours remains unclear. However PRAME 
remains relevant in acute leukaemias for risk 
stratification, to monitor residual disease and as a 
potential target for immunotherapies. 
WT1 gene, encodes a transcription factor 
involved in normal and malignant hematopoiesis [31]. 
In acute leukemia, WT1 mutations have been reported 
in 10% of patients with acute myeloid leukemia (AML). 
However, mutations were also observed in selected 
cases of acute T-lymphoblastic leukemia (T-ALL), as 
well as undifferentiated/biphenotypic leukemia [32]. 
Apart from WT1 mutations, overexpression of WT1 
was found in AML patients and to a lower extent in 
ALL [33] . 
WT1 gene was expressed in 52% of our ALL 
patients. That was comparable to reports showing 
WT1expression in 44 to 86% of ALL [33, 34]. This 
result may depend on the higher sensitivity and 
specificity of the PCR. Alterations of WT1 expression 
(both under- or overexpression) have been described 
in a number of malignancies and premalignant 
syndromes. Remarkably, WT1 overexpression has 
been found in 80–90% of AML and 70–90% of ALL 
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patients, with an even higher frequency at relapse [35-
37]. The upregulation of WT1 is present in all 
leukemia subtypes. In AML, several authors detected 
lower levels of WT1 expression in more differentiated 
AML subtypes (M5) than in less differentiated 
subtypes [38],
 
while others could not support this 
finding [36]. In ALL, a higher frequency of WT1 
expression was found in B-ALL by one author [39] and 
in T-ALL by another [40]. WT1 overexpression was 
also detected in the cerebrospinal fluid of patients with 
B-ALL where it showed a strong association with 
disease relapse [41]. 
Study of relapse free survival among our 
patients expressing WT1 gene showed that those 
patients had better relapse free survival. Our findings 
were in contrary to other studies which identified WT1 
overexpression as an independent adverse prognostic 
factor in acute leukemia associated with an increased 
risk of relapse [38, 42]. Among childhood ALL patients 
by Boublikova et al., 2006 [43], there was a trend 
toward higher WT1 expression in those who relapsed 
but this did not reach statistical significance. A recent 
study by Miglino and his collaegues, 2011 [44] on 100 
patients with intermediate and poor cytogenetic risk 
de novo acute myeloid leukemia receiving 
conventional anthracycline-AraC based therapy was 
done. They observed that WT1 expression above 
2365 was correlated also to longer event-free survival 
(EFS) and overall survival in the two subset of 
patients The positive prognostic value of high WT1 
expression does not have a clear explanation; it may 
be implicated either with WT1 anti-oncogenic function, 
or with the stimulating effect of WT1 oncogene on the 
leukemic cellular cycle, possibly associated with an 
enhanced response to chemotherapy. 
Our study revealed that relapse free survival 
increased significantly among patients coexpressing 
PRAME and WT genes. WT1 gene was expressed in 
10 patients, 9 of them coexpressed PRAME gene 
(which was known to be a marker for better free 
survival and overall survival). This might explain why 
WT1 gene be considered good prognostic factor in 
contrary to other studies. However more studies on 
larger number of patients are needed for better 
understanding the roles of WT1 and PRAME genes in 
the process of leukemogenesis, their significance as a 
prognostic factor, minimal residual disease marker 
and being a possible target for immunotherapy in 
acute leukemia. 
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